David M. Rubenstein - Apr 30, 2025 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Director
Signature
/s/ Brian Sandstrom, As Attorney-in-Fact
Stock symbol
MRNA
Transactions as of
Apr 30, 2025
Transactions value $
$0
Form type
4
Date filed
5/1/2025, 04:34 PM
Previous filing
Aug 7, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise +677 677 Apr 30, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Restricted Stock Units Options Exercise $0 -677 -100% $0.00 0 Apr 30, 2025 Common Stock 677 Direct F1, F2
transaction MRNA Stock Option (Right to Buy) Award $0 +12.8K $0.00 12.8K Apr 30, 2025 Common Stock 12.8K $28.54 Direct F3
transaction MRNA Restricted Stock Units Award $0 +8.12K $0.00 8.12K Apr 30, 2025 Common Stock 8.12K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units convert into common stock on a one-for-one basis.
F2 The shares subject to this restricted stock unit award vested in full on April 30, 2025.
F3 This option will become fully vested and exercisable on the earlier of April 30, 2026, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service.
F4 The shares subject to this restricted stock unit award will vest in full on the earlier of April 30, 2026, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service.